bioAffinity Technologies (BIAF) Cash & Equivalents (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Cash & Equivalents for 6 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 674.59% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (up 674.59% YoY), while the FY2025 annual figure was $6.4 million, up 483.54% from the prior year.
• Cash & Equivalents eased to $3.1 million in Q1 2026 per BIAF's latest filing, from $6.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $13.5 million in Q3 2022 and bottomed at $400000.0 in Q1 2025.
• Historically, Cash & Equivalents has averaged $4.9 million across 5 years, with a median of $3.1 million in 2026.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 90.36% — and 2025, when it surged 913.67%.
• bioAffinity Technologies' Cash & Equivalents stood at $11.4 million in 2022, then sank by 75.28% to $2.8 million in 2023, then sank by 60.83% to $1.1 million in 2024, then soared by 483.54% to $6.4 million in 2025, then sank by 51.96% to $3.1 million in 2026.
• Business Quant data shows BIAF's Cash & Equivalents at $3.1 million in Q1 2026, $6.4 million in Q4 2025, and $7.7 million in Q3 2025.